A Phase III Long Term Study of TO-210

A Phase III Long Term Study of TO-210 in Patients with Acne Vulgaris

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031250482

Enrollment

400

Registered

2025-11-05

Start date

2025-11-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Interventions

TO-210 will be applied once daily after cleansing/washing.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients with acne vulgaris aged 9 years and older at informed consent -Patients with 5-100 inflammatory lesions on the face.

Exclusion criteria

Exclusion criteria: -Patients with acne forms other than acne vulgaris at application site, that may interfere with the study assessments. -Patients with skin diseases or skin infections at application site, that may interfere with the study assessments. -Patients with conditions, which, in the Investigator's opinion, could significantly compromise the patient's safety and/or place the patient at an unacceptable risk.

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
-Lesion count -Investigator's Global Assessment (IGA) score -Physician's Global Assessment (PGA) score -Dermatology Life Quality Index (DLQI) /Children's Dermatology Life Quality Index (C-DLQI) -Scale for Acne Scar Severity (SCAR-S) score	—

Contacts

Public ContactRyuji Azuma

Torii Pharmaceutical Co.,Ltd

ryuji.azuma@torii.co.jp+81-80-6746-6718

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026